Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer.

Trial Profile

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2015

At a glance

  • Drugs Zanolimumab (Primary) ; Aldesleukin
  • Indications Malignant melanoma; Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Mar 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 14 Mar 2012 Additional lead trial investigator (Schrump DS) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top